TheTechno Optimist.

SignateraNatera—Natera reports record Q2 2026 results: 283,000 Signatera tests (+56% YoY), total revenue $753M (+38% YoY), guidance raised to $2.85-2.91BSignateraNatera—Natera presents 35 oncology studies at ASCO 2026, including three oral presentations on MRD-guided cancer careSignateraNatera—Japan's PMDA approves Signatera for colorectal cancer MRD testing, the first PMDA-approved MRD testSignateraNatera—FDA approves Signatera as companion diagnostic for muscle-invasive bladder cancer, the first MRD test to achieve this designation

Natera

Signatera MRD testing, cell-free DNA diagnostics

US$47B market capest. 2004natera.com (opens natera.com)Checked 11 Oct

The brief

Analyst view
  • FDA approved Signatera as companion diagnostic for bladder cancer; Japan approved it for colorectal cancer.
  • Signatera's Q2 2026 tests grew 56% YoY to 283,000; total company revenue $753M (+38% YoY).
  • Full-year 2026 guidance raised to $2.85-2.91B. GALAXY trial shows MRD guides chemotherapy benefit.

Technical approach

As reported
Cell-free DNA

Detecting tumor DNA in blood

Signatera measures circulating tumor DNA in blood by identifying patient-specific tumor mutations and tracking their reappearance in follow-up draws.

MRD testing

Residual disease guidance

After treatment, negative MRD results guide de-escalation; positive results suggest additional therapy. One test detects one cancer cell in 10,000 normal cells.

Bioinformatics

Deep sequencing

Targeted sequencing and proprietary algorithms find tumor mutations at extremely low sensitivity, personalized to each patient's cancer.

Primer